FDA Lifts Partial Clinical Hold on Trials for OncoMed’s Vantictumab

Drug Industry Daily
A A
Cancer drugmaker OncoMed expects to resume enrollment and dosing of new patients for its experimental oncology drug vantictumab within the next few weeks, after the FDA removed a partial clinical hold on its clinical trials.

To View This Article:

Login

Subscribe To Drug Industry Daily